| Cash flow (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 2.98B | 2.94B | 2.94B | -3.98B | 1.02B | 1.78B | 1.64B | 87.00M |
| Depreciation and amortization | 1.13B | 1.11B | 1.15B | 1.13B | 1.17B | 1.15B | 1.15B | 1.16B |
| Stock-based compensation | 176.00M | 266.00M | 135.00M | 138.00M | 136.00M | 126.00M | 137.00M | 133.00M |
| Cash from operations | 6.34B | 4.25B | 3.39B | 796.00M | 1.90B | 4.56B | 1.86B | -745.00M |
| Capital expenditure | -691.00M | -849.00M | -784.00M | -698.00M | -607.00M | -743.00M | -768.00M | -670.00M |
| Free cash flow | 5.65B | 3.40B | 2.61B | 98.00M | 1.29B | 3.81B | 1.09B | -1.42B |
| Acquisitions | -4.00M | -5.00M | -7.00M | -290.00M | -119.00M | -20.00M | -10.00M | -12.00M |
| Cash from investing | -1.88B | -874.00M | -2.00B | -2.09B | -1.02B | -762.00M | -547.00M | -3.35B |
| Dividends paid | -878.00M | -847.00M | -845.00M | -846.00M | -866.00M | -840.00M | -838.00M | -837.00M |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 1.00M | ||
| Net debt issued | -1.77B | -1.52B | -20.00M | 1.12B | -19.00M | -743.00M | -113.00M | -1.67B |
| Cash from financing | -2.69B | -2.32B | -2.03B | -1.38B | 806.00M | -2.33B | 431.00M | -1.59B |
| Net change in cash | 1.77B | 1.06B | -640.00M | -2.67B | 1.68B | 1.46B | 1.74B | -5.68B |
From CVS Health's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.